KR102022231B1 - 중추 신경계의 2차 부종을 치료하기 위한 ｃ1-억제제의 용도 - Google Patents

중추 신경계의 2차 부종을 치료하기 위한 ｃ1-억제제의 용도 Download PDF

Info

Publication number
KR102022231B1
KR102022231B1 KR1020147020461A KR20147020461A KR102022231B1 KR 102022231 B1 KR102022231 B1 KR 102022231B1 KR 1020147020461 A KR1020147020461 A KR 1020147020461A KR 20147020461 A KR20147020461 A KR 20147020461A KR 102022231 B1 KR102022231 B1 KR 102022231B1
Authority
KR
South Korea
Prior art keywords
edema
brain
stroke
inhibitor
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147020461A
Other languages
English (en)
Korean (ko)
Other versions
KR20140107567A (ko
Inventor
크리스토프 클라인슈니츠
마르크 놀테
귀도 스톨
게르하르트 딕나이테
슈테판 슐테
베른하르트 니스반트
잉고 프라그스트
Original Assignee
체에스엘 베링 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 체에스엘 베링 게엠베하 filed Critical 체에스엘 베링 게엠베하
Publication of KR20140107567A publication Critical patent/KR20140107567A/ko
Application granted granted Critical
Publication of KR102022231B1 publication Critical patent/KR102022231B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020147020461A 2011-12-22 2012-12-21 중추 신경계의 2차 부종을 치료하기 위한 ｃ1-억제제의 용도 Active KR102022231B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11195254.5 2011-12-22
EP11195254 2011-12-22
US201261587371P 2012-01-17 2012-01-17
US61/587,371 2012-01-17
PCT/EP2012/076691 WO2013093027A1 (en) 2011-12-22 2012-12-21 Use of c1-inhibitor for the treatment of secondary edema of the central nervous system

Publications (2)

Publication Number Publication Date
KR20140107567A KR20140107567A (ko) 2014-09-04
KR102022231B1 true KR102022231B1 (ko) 2019-09-19

Family

ID=48667767

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147020461A Active KR102022231B1 (ko) 2011-12-22 2012-12-21 중추 신경계의 2차 부종을 치료하기 위한 ｃ1-억제제의 용도

Country Status (10)

Country Link
US (1) US9452203B2 (https=)
EP (1) EP2793935B1 (https=)
JP (1) JP6127063B2 (https=)
KR (1) KR102022231B1 (https=)
CN (1) CN104080474B (https=)
AU (1) AU2012318275B2 (https=)
CA (1) CA2858984C (https=)
DK (1) DK2793935T3 (https=)
ES (1) ES2587863T3 (https=)
WO (1) WO2013093027A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210069016A1 (en) * 2008-11-13 2021-03-11 Gholam A. Peyman Neurodegenerative Disorder Treatment Method
EP3722320A3 (en) 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
RS58351B1 (sr) * 2013-03-15 2019-03-29 Shire Viropharma Inc C1-inh kompozicije i postupci za prevenciju i lečenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze
US20160130324A1 (en) * 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
WO2016081889A1 (en) * 2014-11-21 2016-05-26 Kurt Baekgaard Osther Recombinant c1 esterase inhibitor and use thereof
CA2981321A1 (en) 2015-04-06 2016-10-13 True North Therapeutics, Inc. Humanized anti-c1s antibodies and methods of use thereof
CN108463243B (zh) 2015-11-19 2022-06-14 夏尔人类遗传性治疗公司 重组人c1酯酶抑制剂及其用途
CN110300520B (zh) 2016-10-12 2022-10-04 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007073186A2 (en) * 2005-12-21 2007-06-28 Pharming Intellectual Property Bv Use of c1 inhibitor for the prevention of ischemia-reperfusion injury

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228502A1 (de) 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
DE4222534A1 (de) 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE4244735A1 (de) 1992-08-24 1994-03-31 Behringwerke Ag Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen
JP3941174B2 (ja) 1996-08-26 2007-07-04 富士ゼロックス株式会社 複合材料及びその製造方法
US7053176B1 (en) 1999-09-16 2006-05-30 Altana Pharma Ag Combination of C1-INH and lung surfactant for the treatment of respiratory disorders
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
PT1965831E (pt) * 2005-12-21 2011-10-19 Pharming Intellectual Pty Bv Uso de inibidor c1 para a prevenção da lesão isquémia-reperfusão

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007073186A2 (en) * 2005-12-21 2007-06-28 Pharming Intellectual Property Bv Use of c1 inhibitor for the prevention of ischemia-reperfusion injury

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Immunology Letters 89 (2003) 155-160*

Also Published As

Publication number Publication date
AU2012318275B2 (en) 2016-05-19
CN104080474A (zh) 2014-10-01
EP2793935B1 (en) 2016-05-25
CN104080474B (zh) 2016-04-27
JP2015502389A (ja) 2015-01-22
EP2793935A1 (en) 2014-10-29
CA2858984A1 (en) 2013-06-27
WO2013093027A1 (en) 2013-06-27
US9452203B2 (en) 2016-09-27
DK2793935T3 (en) 2016-09-05
KR20140107567A (ko) 2014-09-04
JP6127063B2 (ja) 2017-05-10
AU2012318275A1 (en) 2013-07-11
CA2858984C (en) 2021-01-05
ES2587863T3 (es) 2016-10-27
HK1201729A1 (zh) 2015-09-11
US20140371425A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
KR102022231B1 (ko) 중추 신경계의 2차 부종을 치료하기 위한 ｃ1-억제제의 용도
Göb et al. Blocking of plasma kallikrein ameliorates stroke by reducing thromboinflammation
Kraft et al. The phosphodiesterase-4 inhibitor rolipram protects from ischemic stroke in mice by reducing blood–brain-barrier damage, inflammation and thrombosis
TW201904990A (zh) 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
US7375076B2 (en) Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tPA) and tPA inhibitors useful therein
HK1201729B (en) Use of c1-inhibitor for the treatment of secondary edema of the central nervous system
JP6289511B2 (ja) 羊水塞栓の治療剤
Elkhrbash The role of angiotensin AT1 and AT2 receptors in the development of apoptosis and inflammation following experimental myocardial infarction
Bhardwaj Ischemic Neuroprotection With Selective κ-Opioid Receptor Agonist Is Gender Specific: P371
Yenari Hsp70 Inhibits Activation of Nuclear Factor κB by Preventing Phosphorylation of Its Inhibitor Protein, IkB: P385
Dichgans The Pattern of Cognitive Performance in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL): P402
Yenari Reversal of Microglial Potentiated Astrocyte Injury by Inducible HSP70: P387
Steinberg Hypothermia Attenuates the Decrease in Phosphorylation of Proteins in Akt Cell Signal Pathway After Permanent Middle Cerebral Artery Occlusion in Rats: P398
Herrup Hypoxic Preconditioning Reduces Select Cell Cycle–Related Processes After Reversible Middle Cerebral Artery Occlusion: P376
Khatri Prospective Evaluation of Treatment of Acute Hypertension in Patients With Intracerebral Hemorrhage Using American Heart Association Guidelines: P368
Yoon Inhibition of Postischemic Inflammation Reduced Early Endogenous Neurogenesis in Rat Stroke Model: P375
Moro Ischemic Tolerance Involves Upregulation of Glutamate Transport Partly Mediated by the TACE/ADAM17-TNF-α Pathway: P381
Zuccarello Local Brain Hypothermia Markedly Reduces Vasogenic Edema Development in a Porcine Intracerebral Hemorrhage Model: P390
Wijman Utility of Magnetic Resonance Imaging in the Diagnosis and Management of Intracerebral Hemorrhage: P370
Steinberg Antiinflammatory Treatment Aids in Cell Survival and Neurogenesis Following Stroke: P383
Rafols Pre-Reperfusion Flushing of Saline Into Ischemic Territory Improves Neurovascular Integrity by Reducing Matrix Metalloproteinase Upregulation in Stroke: P372
Sacco The Short-Term Effect of Atorvastatin on Carotid Artery Wall Elasticity: B-Mode Ultrasound Distensibility Study: P403
Fisher Perfusion and Diffusion Imaging in Acute Focal Cerebral Ischemia: Temporal versus Spatial Resolution: P388
Fisher Novel Peptides With Neuroprotective Effects In Vitro and In Vivo: P395
Kim Activation of FOXO3a Transcription Factor Involves Neuronal Cell Death After Focal Cerebral Ischemia in Rats: P394

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140721

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20171206

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20181211

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20190823

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190910

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190911

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20220728

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20220728

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20230727

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20240729

Start annual number: 6

End annual number: 6